“…Antifungal resistance is now a topic that necessarily includes Candida auris, an emerging fungal pathogen that has gained great importance in recent years due to its intrinsic resistance to antifungals and great ability to spread in the environment, affecting especially immunocompromised patients in the hospital environment. − C. auris was first reported in 2009 at a Japanese hospital and since then, it was associated with disease in more than 30 countries from all continents. ,− In the US, for example, the Centers for Disease Control and Prevention (CDC) reported a significant increase in C. auris infections, from 309 cases in 2013 to 1012 cases in 2018 . The impact of the emergence of C. auris on public health is directly linked to the fact that C. auris can be resistant to azoles, echinocandins, and polyenes. , In fact, multidrug-resistant (MDR) isolates have been frequently reported worldwide, including resistance to two or more classes of antifungals. ,− Some of the C. auris isolates show an alarmingly low susceptibility to amphotericin B. ,,,,, In this scenario, drugs affecting C. auris growth have been continuously investigated, with considerable progress reported for molecules affecting the fungal mitochondria, plasma membrane, biofilms, and cell wall. , …”